Abstract: A novel class of dithiane and disulfone compound is described. These compounds are pharmaceutically active as coronary dilating agents and thus can be used therapeutically in cases of insufficient cardiac blood supply, i.e., in the treatment of angina pectoris. A preferred compound is N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-N-methyl-m-dithiane-2-p ropylamine-1,1-3,3-tetraoxide.

Abstract: Method for preparing a lactone reaction product comprising reacting an alkenylsuccinic acid under substantially anhydrous conditions in the presence of a protonating agent and at an elevated temperature ranging up to about 100.degree. C., and a motor fuel composition containing said lactone reaction product.

Abstract: 2-(Substituted phenylimino)-2H-quinolizines are effective antiulcerogenic drugs.

Abstract: Thianthrene is prepared by adding sulfur monochloride to an excess of benzene in the presence of aluminum chloride, and reacting at a temperature of 60.degree. to 80.degree. C to form thianthrene as an insoluble thianthrene-aluminum chloride complex; separating the complex by filtration, slurrying the complex in an inert organic liquid; treating the slurry with a Lewis base, such as ammonia to free the thianthrene from the complex and recovering a relatively high purity thianthrene product.

Abstract: 9-Xanthylaminoalkylpyridine derivatives are prepared. These compounds are inhibitors of gastric acid secretion.

Abstract: The present invention relates to a process for the manufacture of 2,2-disubstituted propiolactones via the pyrolysis of methylene diisoalkylate in the vapor phase over a fixed bed catalyst system. The reaction of the invention is as follows: ##SPC1##Wherein R is alkyl of from 1 to 4 carbon atoms and R.sup.1 is alkyl of from 1 to 4 carbon atoms or phenyl. The catalyst comprises an oxide of a metal selected from the group Ag, U, Zn, Ti, Zr, Th, Ta, Nb, Mo, W, and Sn on a suitable support. A preferred catalyst is the metal oxide-silica gel complex which results from heating the calcined residue of a salt of a metal selected from the group consisting of Ta, Ti, Nb and Zr supported upon a silica gel in the presence of nitrogen and steam at a temperature of from about 650.degree. C. to about 1000.degree. C. The process is operable at temperatures from about 240.degree. C. to about 360.degree. C. with contact times ranging from about 0.1 second to about 30.0 seconds.

Abstract: Pharmaceutical compositions comprising, in unit dosage form, from about 0.5 mg. to about 100 mg. of a compound of the formula ##SPC1##Wherein R and R' are hydrogen, methyl or ethyl, R.sub.1 is hydrogen or lower alkyl of 1 through 3 carbon atoms, R.sub.2 is hydrogen, lower alkyl of 1 through 3 carbon atoms, fluorine, chlorine, bromine, nitro, trifluoromethyl or lower alkylthio of 1 through 3 carbon atoms, and the pharmacologically acceptable acid addition salts thereof, in association with a pharmaceutical carrier. The process is the administration of the above compositions to humans or animals at a dose of from about 0.01 mg./kg./day to about 2 mg./kg./day for anti-anxiety or anti-depressant effects.

Abstract: Ester and amide derivatives of three-hydroxycitric acid .gamma.-lactone inhibit fatty acid synthesis in biological systems and are useful in the treatment of obesity and in correcting conditions of lipid abnormalities.

Abstract: Ester and amide derivatives of three-hydroxycitric acid .gamma.-lactone inhibit fatty acid synthesis in biological systems and are useful in the treatment of obesity and in correcting conditions of lipid abnormalities.

Abstract: The present invention relates to novel .alpha.-benzylidene-.gamma.-butyrolactone derivatives and processes for the manufacture of them. Further, the present invention pertains to the fungicidal composition containing the same and use thereof.

Abstract: New amino derivatives of 6-phenylisoxazolo[5,4-b]pyridines have the general formula ##SPC1##They are useful as anti-inflammatory agents.

Abstract: Compounds having the structure ##SPC1##And the pharmaceutically acceptable salts thereof; wherein Z is oxygen, sulfur or methylene; R.sub.1 is hydrogen, halogen, alkyl, aryl or arylalkyl; R.sub.2 is hydrogen, alkyl, aryl, or arylalkyl; R.sub.3 is hydrogen, alkyl, aryl or arylalkyl; and R.sub.4 is hydrogen, halogen, alkyl, phenyl, dialkylamidosulfonyl or trifluoromethyl; have useful central nervous system activity.